SCHEMBL21144129

SCHEMBL21144129

COc1cc(NC2CCC(F)(F)CC2)nc(S(C)(=O)=O)n1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
KCNH2 Q12809 1/20 0.41
IDH1 O75874 7/20 0.39
SCN9A Q15858 1/20 0.38
PTGS2 P35354 2/20 0.36
TEAD2 Q15562 1/20 0.35
IDH2 P48735 2/20 0.34
FFAR2 O15552 1/20 0.33
ITGB1 P05556 1/20 0.33
ITGA4 P13612 1/20 0.33
BRD4 O60885 1/20 0.33
POLB P06746 1/20 0.33
GFER P55789 1/20 0.33
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
CHIA Q9BZP6 1/20 0.32
EHMT2 Q96KQ7 1/20 0.32
EHMT1 Q9H9B1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21144171 0.85 KCNH2 (0.40) LMNASMN1; SMN2KCNH2IDH1SCN9A
SCHEMBL31127173 0.84 KCNH2 (0.37) LMNASMN1; SMN2KCNH2IDH1SCN9A
SCHEMBL21144284 0.84 KCNH2 (0.37) LMNASMN1; SMN2KCNH2IDH1SCN9A
SCHEMBL31127300 0.82 KCNH2 (0.47) KCNH2IDH1SCN9APTGS2IDH2
SCHEMBL21143837 0.82 KCNH2 (0.47) KCNH2IDH1SCN9APTGS2IDH2
SCHEMBL31127073 0.81 GPR119 (0.36) LMNASMN1; SMN2KCNH2IDH1SCN9A
SCHEMBL21144088 0.81 GPR119 (0.36) LMNASMN1; SMN2KCNH2IDH1SCN9A
SCHEMBL21143887 0.81 PTGS2 (0.54) LMNASMN1; SMN2KCNH2IDH1PTGS2
SCHEMBL21166208 0.79 KCNH2 (0.33) LMNASMN1; SMN2KCNH2IDH1SCN9A
SCHEMBL31127190 0.79 KCNH2 (0.33) LMNASMN1; SMN2KCNH2IDH1SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 LMNA 1529/4885SMN1; SMN2 1109/4885KCNH2 22/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 LMNA 1529/4885SMN1; SMN2 1109/4885KCNH2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.